Clinical Study of Allogeneic Hematopoietic Stem Cell Transplanta-tion Patients with Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus
10.19746/j.cnki.issn1009-2137.2024.02.036
- VernacularTitle:异基因造血干细胞移植后CMV和EBV共激活患者的临床研究
- Author:
Zhi-Wei WANG
1
;
Qiong LIU
;
Hai-Ying SUN
Author Information
1. 徐州医科大学附属医院血液科,江苏徐州 221000
- Keywords:
allogeneic hematopoietic stem cell transplantation;
cytomegalovirus;
Epstein-Barr virus;
co-reactivation;
prognosis
- From:
Journal of Experimental Hematology
2024;32(2):561-567
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics and risk factors of cytomegalovirus(CMV)and Epstein-Barr virus(EBV)co-reactivation after allogeneic hematopoietic stem cell transplantation(allo-HSCT)and its influence on prognosis.Methods:The clinical data of 222 patients who received allo-HSCT from January 2015 to December 2020 were collected,and the patients were divided into groups according to the occurrence of CMV and EBV infection.Kaplan-Meier method was used for survival analysis,and Cox proportional hazard regression model was used to analyze the risk factors of co-reactivation of CMV and EBV.Results:After allo-HSCT,there were 30 patients with co-reactivation of CMV and EBV(CMV++EBV+group),101 patients with CMV viremia(CMV+group),149 patients with EBV viremia(EBV+group),and 28 patients with CMV and EBV inactivation(CMV-+EBV-group).Compared with the other groups,the incidence of acute graft-versus-host disease(aGVHD)and hemorrhagic cystitis(HC)was higher in CMV++EBV+groups(53.3％vs 42.6％,36.9％,17.9％,P＜0.001;36.7％vs 32.7％,22.8％,10.7％,P=0.042).The incidence of post-transplant lymphoproliferative disease(PTLD)in CMV++EBV+group was similar to CMV+group and EBV+group(3.3％vs 3.0％,3.4％,P=0.811).Univariate and multivariate analysis showed that the persistent time of CMV and EBV after transplantation were independent risk factors for co-reactivation of CMV and EBV.Compared with the other groups,the 2-year overall survival(OS)rate and 2-year disease-free survival(DFS)rate of patients inCMV++EBV+group were lower(46.7％vs 74.9％,83.4％,71.4％,P＜0.001;46.7％vs 70.9％,79.5％,69.9％,P=0.002),and 2-year non-recurrence mortality(NRM)was higher(48.2％vs 22％,13.6％,18.7％,P＜0.001).Conclusion:The persistent time of CMV and EBV after transplantation are independent risk factors for patients with co-reactivation of CMV and EBV.Patients with co-reactivation of CMV and EBV had lower OS and DFS rate and higher NRM,suggesting that the clinical prognosis of the patients are worse.
